Researchers study the role of obesity and inflammation in the development of Alzheimer's disease
A study by the University of Barcelona with the participation of researchers from Ace Alzheimer Center Barcelona, recently published in the journal Cell & Bioscience, has evaluated the beneficial effects of the repeated administration of Dexibuprofen - a drug similar to Ibuprofen - in reducing risk factors associated with Alzheimer's disease in a transgenic mouse model, that is, mice genetically modified to reproduce Alzheimer's disease.
This study aimed to evaluate the effects of Dexibuprofen treatment on the progression of Alzheimer's disease in transgenic mice fed with a high-fat diet. The animals were divided into two large groups, those that received conventional feed and those that received the fatty diet and, in turn, within these groups, half of them received the treatment with Dexibuprofen for 3 months and the other half did not.
The results obtained showed that Dexibuprofen improved metabolic alterations in mice fed with a high-fat diet, such as increased body weight or blood glucose and insulin levels. Alzheimer's disease is a pathology of unknown origin, but in which various risk factors have been detected, such as obesity and metabolic disorders that are involved in its development and worsening of cognitive and memory processes.
In this study, it has been seen that Dexibuprofen treatment also improved cognitive decline, neuroinflammation, oxidative stress, and the accumulation of senile beta-amyloid plaques.
Another advantage of the potential use of Dexibuprofen for the treatment of Alzheimer's disease is that, as it is a drug that concentrates all its therapeutic potential, the dose administered could be reduced while maintaining effectiveness and reducing the derived adverse effects. In the case of repeated administration of anti-inflammatory drugs, the most common and dangerous adverse effect is gastrointestinal damage.
Amanda Cano, postdoctoral researcher at Ace Alzheimer Center Barcelona and collaborator of this study highlights “the importance of basic and pre-clinical research on Alzheimer's disease to make new therapies emerge and transfer them to the clinical level to advance an effective treatment for this type of dementia”.
This study is funded by a SAF project granted by the Ministry of Economy and Competitiveness and led and developed by the research group of Dr. and Professor Antonio Camins, from the Department of Pharmacology of the Faculty of Pharmacy of the University of Barcelona, and a member of the Center for Biomedical Research in Neurodegenerative Diseases Network (CIBERNED).